Monoclonal antibody agent developer NeoRx has completed a privateplacement of equity to institutional investors in a deal worth$7 million to the Seattle-based firm. The company will use thefunds to pursue continued clinical trials of its Biostent
Monoclonal antibody agent developer NeoRx has completed a privateplacement of equity to institutional investors in a deal worth$7 million to the Seattle-based firm. The company will use thefunds to pursue continued clinical trials of its Biostent andAvicidin therapy agents, according to president and CEO Dr. PaulAbrams.
NeoRx is awaiting final word from the Food and Drug Administrationon its Verluma agent for imaging small-cell lung cancer. An FDApanel recommended Verluma for approval in December (SCAN 12/27/95).NeoRx will receive $4.5 million from Verluma licensee Du PontMerck Pharmaceutical when the product is approved.
New Literature Review Assesses Merits of Cardiac MRI After Survival of Sudden Cardiac Arrest
April 19th 2024While noting inconsistencies with the diagnostic yield of cardiac MRI in patients who survived sudden cardiac arrest, researchers cited unique advantages in characterizing ischemic cardiomyopathy (ICM) and facilitating alternate diagnoses.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.